Duchenne muscular dystrophy
Locanabio Announces Shutdown, Aids Staff in Job Transition
Locanabio is set to cease operations by the yearâs end, succumbing to the challenging financial landscape that continues to affect ...
Catalent Braces for Potential Revenue Setback Following Sarepta’s Gene Therapy Trial Disappointment
Catalent, having overcome the challenges posed by the pandemic, now faces another potential setback in the form of what analysts ...
Santhera and Catalyst win FDA approval for Duchenne drug Agamree
The FDA’s recent green light for Agamree (vamorolone) in the treatment of Duchenne muscular dystrophy (DMD) has ignited a wave ...
PTC cuts jobs as Europe withdraws approval for its DMD drug
PTC Therapeutics has announced an expansion of its previously planned workforce reductions as European regulatory concerns cast a shadow over ...
PTC Therapeuticsâ Translarna at risk of losing EU approval after failing to impress FDA for DMD
PTC Therapeutics is facing a significant setback as it seeks to maintain approval for its Duchenne muscular dystrophy (DMD) therapy, ...
Another Phase 3 flop for FibroGen as DMD drug fails to improve mobility
FibroGenâs troubles continue to mount. The biotech announced its fourth phase 3 failure in four months after the market closed ...
SV95C is approved by EMA as the digital primary endpoint for DMD trials
Source – Sysnav Healthcare The European Medicines Agency (EMA) has granted approval for the utilization of a digital measurement employing ...
Sarepta Therapeutics Sells Rare Pediatric Disease Priority Review Voucher for $102 Million to Boost Research and Development
Source – Sarepta Therapeutics On July 5, 2023, Sarepta Therapeutics, a leading company in precision genetic medicine for rare diseases, ...
FDA’s Peter Marks Overrides Reviewers’ Rejection to Approve Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy
Despite the FDA review teams initially leaning against approving Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy, a memo reveals that ...
Sarepta Therapeutics Makes History with FDA Approval of Elevidys, the First Gene Therapy for Duchenne Muscular Dystrophy
Source – Sarepta Therapeutics On June 22, 2023, Sarepta Therapeutics made an announcement regarding the accelerated approval granted by the ...
Sarepta’s Breakthrough DMD Gene Treatment, Elevidys, Triumphs FDA Hurdles at $3.2M
The speedy approval of Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy has been achieved after several delays and a close ...
